Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Perioperative anemia is very common in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA). This study retrospectively analyzes the use of rHuEPO and iron sucrose in patients undergoing total hip and knee arthroplasty in order to observe the short-term efficacy and safety of rHuEPO and iron sucrose.
This study aims to explore whether short-term use of rHuEPO and iron sucrose can improve postoperative anemia and promote postoperative rehabilitation after hip and knee arthroplasty. According to different therapies of perioperative anemia , included subjects would be divided into rHuEPO monotherapy group, iron sucrose monotherapy group, rHuEPO combined with iron sucrose group and control group (without rHuEPO and iron sucrose).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| rHuEPO monotherapy group | rHuEPO was administrated during hospitalization period. |
| |
| iron sucrose monotherapy group | Iron sucrose was administrated during hospitalization period. |
| |
| rHuEPO combined with iron sucrose group | rHuEPO combined with iron sucrose was administrated during hospitalization period. |
| |
| control group | Subjects didn't be administrated with rHuEPO and/or iron sucrose during hospitalization period. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| rHuEPO | Drug | rHuEPO was administrated daily with 10000 IU or 20000 IU |
|
| Measure | Description | Time Frame |
|---|---|---|
| Differences in changes of Hb level in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group. | Changes of Hb level =Hb level in postoperative 7d - Hb level in operation day | Operation day to postoperative day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| Differences in change of red blood cells count(RBC) in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group. | Changes of RBC =RBC in postoperative day 7 - RBC in operation day | Operation day to postoperative day 7 |
| Differences in change of hematokrit (HCT) in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients with serious absence of clinical data
Patients with rHuEPO contraindication
Patients definitely allergic to iron sucrose injection
Patients with coagulation dysfunction
Not provided
Not provided
Patients undergoing total hip and knee arthroplasty
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wei Wang, PhD | Contact | 86-18612672533 | wangwei4531@pumch.cn | |
| Rui Wang, Master | Contact | 86-13918856408 | fdwangrui@126.com |
| Name | Affiliation | Role |
|---|---|---|
| Wei Wang, PhD | Peking Union Medical College Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking Union Medical College Hospital | Recruiting | Beijing | Beijing Municipality | 100730 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23118371 | Background | Watts CD, Pagnano MW. Minimising blood loss and transfusion in contemporary hip and knee arthroplasty. J Bone Joint Surg Br. 2012 Nov;94(11 Suppl A):8-10. doi: 10.1302/0301-620X.94B11.30618. | |
| 20624257 | Background | Na HS, Shin SY, Hwang JY, Jeon YT, Kim CS, Do SH. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion. 2011 Jan;51(1):118-24. doi: 10.1111/j.1537-2995.2010.02783.x. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018798 | Anemia, Iron-Deficiency |
| ID | Term |
|---|---|
| D000747 | Anemia, Hypochromic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077605 | Ferric Oxide, Saccharated |
| C066317 | ferryl iron |
| ID | Term |
|---|---|
| D005290 | Ferric Compounds |
| D058085 | Iron Compounds |
| D007287 | Inorganic Chemicals |
| D005937 | Glucaric Acid |
Not provided
Not provided
Not provided
Not provided
Not provided
| Iron sucrose | Drug | Iron sucrose was administrated daily with 100mg or 200mg |
|
|
Changes of HCT =HCT level in postoperative day 7 - HCT level in operation day |
| Operation day to postoperative day 7 |
| Differences in change of allogeneic transfusion rate(%) in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group. | Transfusion rate is defined as the ratio of numbers subjected to blood transfusion in each group subjects. Blood transfusion volume is defined as the amount of blood transfusion during operation day and postoperative period. | Operation day to postoperative day 7 |
| Differences in change of allogeneic blood transfusion volume in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group. | Allogeneic blood transfusion volume is defined as the amount of blood transfusion volume from operation day to postoperative day 7 Blood transfusion volume is defined as the amount of blood transfusion during operation day and postoperative period. | Operation day to postoperative day 7 |
| Difference in postoperative hospital days in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group. | Postoperative hospital days is defined as the number of days from operation day to hospital discharge. | Up to 4 months |
| Comparing differences of blood loss volume in each group. | Blood loss volume is defined as the total volume of intraoperative bleeding and postoperative drainage. | Operation day to postoperative day 7 |
| Comparing the rate of anemia between operation day and post-operation day 7 in each group. | According to 2011 World Health Organization(WHO) anemia standard，Hb< 130g/L for adult men and Hb < 120g/L for non-pregnant women are defined as anemia. | Operation day to postoperation day 7 |
| Differences in changes of platelet count in rHuEPO, iron sucrose, rHuEPO combined with iron sucrose and control group. | Changes of platelet count =platelet count in postoperative 7d - platelet count in operation day | Operation day to postoperative day 7 |
| Safety of rHuEPO and/or iron sucrose | Adverse events and serious adverse events | Form operation day to postoperative day 7 |
| 18349173 | Background | Conlon NP, Bale EP, Herbison GP, McCarroll M. Postoperative anemia and quality of life after primary hip arthroplasty in patients over 65 years old. Anesth Analg. 2008 Apr;106(4):1056-61, table of contents. doi: 10.1213/ane.0b013e318164f114. |
| 25050095 | Background | Bou Monsef J, Boettner F. Blood management may have an impact on length of stay after total hip arthroplasty. HSS J. 2014 Jul;10(2):124-30. doi: 10.1007/s11420-014-9384-x. Epub 2014 Apr 8. |
| 24135037 | Background | Lin DM, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transfus Med Rev. 2013 Oct;27(4):221-34. doi: 10.1016/j.tmrv.2013.09.001. Epub 2013 Oct 15. |
| 27314459 | Background | Voorn VM, van der Hout A, So-Osman C, Vliet Vlieland TP, Nelissen RG, van den Akker-van Marle ME, Dahan A, Marang-van de Mheen PJ, van Bodegom-Vos L. Erythropoietin to reduce allogeneic red blood cell transfusion in patients undergoing total hip or knee arthroplasty. Vox Sang. 2016 Oct;111(3):219-225. doi: 10.1111/vox.12412. Epub 2016 Jun 17. |
| 24219367 | Background | Tran DH, Wong GT, Chee YE, Irwin MG. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period. Expert Opin Biol Ther. 2014 Jan;14(1):51-61. doi: 10.1517/14712598.2014.858116. Epub 2013 Nov 13. |
| 30022832 | Background | Li Y, Yin P, Lv H, Meng Y, Zhang L, Tang P. A meta-analysis and systematic review evaluating the use of erythropoietin in total hip and knee arthroplasty. Ther Clin Risk Manag. 2018 Jul 10;14:1191-1204. doi: 10.2147/TCRM.S159134. eCollection 2018. |
| 12237728 | Background | Crosby E. Perioperative use of erythropoietin. Am J Ther. 2002 Sep-Oct;9(5):371-6. doi: 10.1097/00045391-200209000-00003. |
| 25440391 | Background | Clevenger B, Richards T. Pre-operative anaemia. Anaesthesia. 2015 Jan;70 Suppl 1:20-8, e6-8. doi: 10.1111/anae.12918. |
| 27996086 | Background | Munoz M, Acheson AG, Auerbach M, Besser M, Habler O, Kehlet H, Liumbruno GM, Lasocki S, Meybohm P, Rao Baikady R, Richards T, Shander A, So-Osman C, Spahn DR, Klein AA. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017 Feb;72(2):233-247. doi: 10.1111/anae.13773. Epub 2016 Dec 20. |
| 23581484 | Background | Munoz M, Gomez-Ramirez S, Cuenca J, Garcia-Erce JA, Iglesias-Aparicio D, Haman-Alcober S, Ariza D, Naveira E. Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion. 2014 Feb;54(2):289-99. doi: 10.1111/trf.12195. Epub 2013 Apr 15. |
| D000090463 |
| Iron Deficiencies |
| D019189 | Iron Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D013400 |
| Sugar Acids |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D006880 | Hydroxy Acids |
| D002241 | Carbohydrates |